X
Xiamen Yanzhiwu Bioengineering
A healthy food production company
About Xiamen Yanzhiwu Bioengineering
Xiamen Yanzhiwu Bioengineering, which now operates as Xiamen Yan Palace Bird's Nest Industry Co., Ltd., is a prominent player in China's edible bird's nest industry. The company was established in 1997 by its founder, Huang Jian. Huang, a former mathematics teacher, transitioned into business in 1992 and identified an opportunity in the bird's nest market while working in Singapore. He observed that bird's nest products in China were primarily sold in pharmacies, which limited their accessibility. In response, he founded the company, initially named "Shuangdanma," to sell bird's nests through more accessible retail counters.
A significant milestone occurred in 2002 when the company introduced a "store + kitchen" model, offering freshly stewed bird's nest products and enabling same-day order, production, and consumption. A pivotal moment came in 2012 with the launch of "Wan Yan," a ready-to-eat bottled bird's nest product, which broadened the consumer base by offering a more convenient option. The company has demonstrated a commitment to setting industry standards; in 2014, Huang Jian led the drafting of the first industry standard for bird's nest quality grades. Xiamen Yanzhiwu went public on the Hong Kong Stock Exchange on December 12, 2023.
The core business revolves around the research, development, production, and sale of high-quality bird's nest products. The product portfolio is diverse, including ready-to-eat bird's nests like the "Wan Yan" series, freshly stewed bird's nests, dry bird's nests, and other derivative products such as bird's nest pastries, chocolates, and beverages. The company serves a broad market through a multi-channel sales strategy. This includes a robust offline presence with hundreds of self-operated and distributor-run stores across numerous cities, as well as a strong online footprint on major e-commerce platforms like Tmall and JD.com. Revenue is generated through direct sales to consumers both online and offline, and through sales to a network of distributors.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Dec 2023 | $16M | $64M | Value Partners · PT Anugerah Citra Walet Indonesia · PT Esta Indonesia · PT Niaga Cakrawala Sukses | ↗ |
Growth signals
Latest recorded traffic for Xiamen Yanzhiwu Bioengineering is 5.7K monthly website visits, up 418.2% over the last three months. Xiamen Yanzhiwu Bioengineering's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xiamen Yanzhiwu Bioengineering in the Xiamen ecosystem
The Xiamen Yanzhiwu Bioengineering office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Value Partners- PIPT Anugerah Citra Walet Indonesia
- PIPT Esta Indonesia
- PSPT Niaga Cakrawala Sukses
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xiamen Yanzhiwu Bioengineering on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xiamen Yanzhiwu Bioengineering’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.